|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cognitive deficits in schizophrenia 显示文摘 | Gold JM Harvey PD | 1993 | Psychiatr Clin North Am1993，16，： | 1 |
| 2 | Cognitive deficits in schizophrenia显示文摘 | Harvey PD | 1993 | Psychiatr Clin Nort Am1993，16，： | 1 |
| 3 | Cognitive deficits in schizophrenia显示文摘 | Gold JM Harvey PD | 2003 | Psychiatr Clin North Am (schizophrenia)2003，16，2： | 1 |
| 4 | Administration and interpretation of the Trail Making Test 显示文摘 | Bowie CR Harvey PD | 2006 | Nat Protoe2006，1，5： | 1 |
| 5 | Improvementin cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schlzophrenia显示文摘 | Harvey PD Mehzer H Simpson GM | 2004 | Schizophr Res2004，66，23： | 1 |
| 6 | Treatment of cognitive impairment in early psychosis:a comparison of risperidone and haloperidol in a large long-term trial显示文摘 | Harvey PD Rabinowitz J Eerdekens M | | 0，，10： | 1 |
| 7 | Ziprasidone:efficacy,tolerability,and emerging data on wide-ranging effectiveness 显示文摘 | Harvey PD Bowie CR | 2005 | Expert Opin Pharmacother2005，6，2： | 1 |
| 8 | Convergent validity and neuropsychological correlates of the schedule for the assessment of negative symptoms (SANS) attention subscale 显示文摘 | Vadhan NP Serper MR Harvey PD | 2001 | J Nerv Ment Dis2001，189，9： | 1 |
| 9 | Reduction offunctional disability with atypical antipsychotic treat-ment :A randomized long term comparison of ziprasidoneand halopcridone显示文摘 | Harvey PD Pappadopulos E Lombardo IA | 2009 | Schizophr Res2009，115，1： | 1 |
| 10 | Ziprasidone:efficacy,tolerabicity,and emerging data on wide ranging effectiveness显示文摘 | Bowie CR | 2005 | Expert opin Pharma Cother2005，6，2： | 1 |
| 11 | Correlates of change in functional status of institutionalized geriatric schizophrenic patients:focus on medical comorbidity显示文摘 | Friedman JI Harvey PD McGurk SR | 2002 | Am J Psychiatry2002，159，8： | 1 |
| 12 | Ziprasidone : efficacy tolerability and emerging data on wide ranging effectiveness 显示文摘 | Harvey PD Bowie CR | 2005 | Expert Opin Pharmacother2005，6，： | 1 |
| 13 | Reduction of functional disability with atypical antipsychotic treatment:a randomized long term comparison of ziprasidone and haloperidol显示文摘 | Harvey PD Pappadopulos E Lombardo I | 2009 | Schizophr Res2009，115，1： | 1 |
| 14 | Negative symptoms and cognitive deficits:what is the nature of their relationship显示文摘 | Harvey PD Koren D Reichenberg A | | 0，，02： | 1 |
| 15 | Cognition in schizophrenia: impairments, determinants, and functional importance 显示文摘 | Bowie CR Harvey PD | 2005 | Psychia Clin North Am2005，28，： | 1 |
| 16 | Rates and predictors of adherence with atypical antipsychotic medication:a follow-up study of adolescent inpatients显示文摘 | Pogge DL Singer MB Harvey PD | 2005 | J Child Adolesc Psychopharmacol2005，15，6： | 1 |
| 17 | Ziprasidone: efficacy, tolerability, and emerging data on wide - ranging effectiveness 显示文摘 | Harvey PD Bowie CR | 2005 | Expert Opin Pharmacother2005，6，2： | 1 |
| 18 | Zipmsidone: efficacy, tolerability and emerging data on wide-ranging effectiveness显示文摘 | Harvey PD Bowie CR | 2005 | Expert Opin Phar- maeother2005，6，： | 1 |
| 19 | Determinants of every- body outcomes in schizophrenia: the influences of cognitive im- pairment, functional capacity, and symptoms显示文摘 | Leifker FR Bowie CR Harvey PD | 2009 | Schizophr Res2009，115，1： | 1 |
| 20 | Ziprasidone : efficacy, tolerabicity, and emerging data on wider anging effectiveness 显示文摘 | Harvey PD Bowie CR | 2005 | Expea Opin pharmacother2005，6，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员